Monteverde law firm investigates NextCure merger with Avere Therapeutics
Attorney advertising notices from two New York investor-rights firms say NextCure shareholders would own about 1.21% of the combined company if the proposed deal closes.
A second shareholder-law-firm notice has emerged over NextCure, Inc.'s proposed merger with Avere Therapeutics, Inc., adding Halper Sadeh LLC to an earlier investigation announced by Monteverde & Associates PC. Both attorney advertising releases say that, after closing, NextCure shareholders are expected to own approximately 1.21% of the combined company. Halper Sadeh said it is examining whether NextCure and its board of directors failed to obtain the best possible price, ran a sales process free of conflicts, and disclosed all material information needed for shareholders to evaluate the transaction. The firm said it may seek increased consideration, additional disclosures, or other relief and invited shareholders to contact Daniel Sadeh or Zachary Halper at no cost. Monteverde's earlier notice similarly framed its review around whether the deal is fair to shareholders and promoted the firm's litigation record.
- merger: A combination of two companies into a single business.
- fiduciary duties: Legal obligations requiring directors to act in shareholders' best interests.
- common stock: Standard company shares that represent ownership in a business.